OncoMatch/Clinical Trials/NCT06810804
A Phase IIa Study to Evaluate NBQ72S
Is NCT06810804 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies NBQ72S for breast cancer.
Treatment: NBQ72S — A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1,500/mm³ or ≥1.5 x 10⁹/L; Platelet count ≥100,000/mm³ or ≥100 x 10⁹/L; Hemoglobin ≥9 g/dL
Kidney function
Serum creatinine ≤1.5 x ULN or estimated creatinine clearance ≥50 mL/min. In equivocal cases, a 24-hour urine collection test can be used to estimate the creatinine clearance more accurately
Liver function
Total serum bilirubin ≤1.5 x ULN; if the tumor involves the liver, or if the patient has a history of Gilbert's syndrome, total bilirubin must be <3 x ULN; AST and ALT ≤2.5 x ULN; if the tumor involves the liver, these values must be ≤5.0 x ULN
adequate bone marrow function, including: 1. Absolute neutrophil count (ANC) ≥1,500/mm³ or ≥1.5 x 10⁹/L; 2. Platelet count ≥100,000/mm³ or ≥100 x 10⁹/L; 3. Hemoglobin ≥9 g/dL; adequate renal function, including: a. Serum creatinine ≤1.5 x upper limit of normal (ULN) or estimated creatinine clearance ≥50 mL/min. Note: In equivocal cases, a 24-hour urine collection test can be used to estimate the creatinine clearance more accurately; adequate hepatic function, including: 1. Total serum bilirubin ≤1.5 x ULN; if the tumor involves the liver, or if the patient has a history of Gilbert's syndrome, total bilirubin must be <3 x ULN; 2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN; if the tumor involves the liver, these values must be ≤5.0 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify